Roche grabs first breast cancer immunotherapy approval

Mar 11, 2019

Roche’s Tecentriq is now the first immunotherapy drug approved by the FDA for the treatment of breast cancer.

Tecentriq, to be given with chemotherapy, was approved for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases.

In a trial of 900 women, those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone.

Read the press release.

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments